Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

104.28 +0.43 (+0.41%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by... 
Via Benzinga
Exposures Product Safety
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
Stocks surged as weak economic data raised hopes for Fed rate cut. S&P 500 up 1.2%, Nasdaq 100 up 1.5%, Dow Jones up 0.6%. Spotify shares jump 17% on earnings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
Shares have risen markedly over the past two days and gained again Tuesday. 
Via Investor's Business Daily
Looking At Novartis's Recent Unusual Options Activity
Via Benzinga
Novartis AG (NYSE: NVS) Highlighted for Surprising Price Action
Via Investor Brand Network
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
NVS earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth. 
Via Benzinga
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fueled much of the market’s upside since 2023. Index futures rose... 
Via Benzinga
Topics Bonds
Exposures Debt Markets
Top Analyst Reports For Novartis, American Express & ConocoPhillips
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP). 
Via Talk Markets
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically." 
Via Investor's Business Daily
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed. 
Via Benzinga
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
These income stocks look like good options at current levels. 
Via The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction. 
Via Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
Think globally with this high-yielding ETF. 
Via The Motley Fool
Topics ETFs
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities. 
Via Benzinga
SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today
SoundHound AI stock is falling on Wednesday as investors in SOUN are worried about the company's plans for a secondary offering. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost
Alibaba stock is up on Wednesday as investors in BABA react to positive comments from cofounder Jack Ma concerning its leadership team. 
Via InvestorPlace
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts
Novartis layoffs will see the healthcare company cut 680 jobs in the U.S. and Switzerland over the next two to three years. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho... 
Via Benzinga
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report
Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools. 
Via Benzinga
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
Via Benzinga
Exposures Product Safety
Why Is Novartis Stock Trading Higher On Thursday?
Novartis to file Pluvicto pre-taxane label expansion in 2H 2024 based on Phase 3 PSMAfore study data. Updated overall survival results show HR<1.0 in ITT population. rPFS consistent. Safety profile... 
Via Benzinga
Harnessing AI for Drug Discovery: Top 3 Stocks to Watch
As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund
Norway's sovereign wealth fund has just five equity investments that represent nearly 13% of its total equity allocation. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.